I'm LongbridgeAI, I can summarize articles.Satellos reported a Q2 FY26 net loss of USD 11.7 million, widening from USD 5.6 million previously. R&D expenses more than doubled to USD 9.6 million due to increased study and CMC costs, while G&A rose 31.1% to USD 2.5 million. Cash reserves reached USD 61.8 million, supporting operations through 2027. The company noted FDA Fast Track designation for SAT-3247, with pediatric Phase 2 data expected in Q4 2026.
- Satellos posted a Q2 net loss of USD 11.7 million, widening from USD 5.6 million a year earlier. * R&D expense more than doubled to USD 9.6 million, driven by higher TRAILHEAD and BASECAMP study costs and CMC spending. * G&A costs climbed 31.1% to USD 2.5 million on higher headcount, Nasdaq-related public reporting fees, and other professional services. * Cash, cash equivalents, short-term investments rose to USD 61.8 million at June 30, providing expected runway through 2027. * SAT-3247 won FDA Fast Track designation; BASECAMP pediatric Phase 2 data due in Q4 2026, TRAILHEAD update also planned in Q4. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131702PRIMZONEFULLFEED9809906) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)